Journal of Internal Medicine Concepts & Practice ›› 2023, Vol. 18 ›› Issue (03): 197-200.doi: 10.16138/j.1673-6087.2023.03.013
• Review article • Previous Articles Next Articles
ZHANG Huijian, LI Guisen(
)
Received:2022-09-15
Online:2023-06-30
Published:2023-08-07
CLC Number:
ZHANG Huijian, LI Guisen. An update on complement targeted treatment of IgA nephropathy[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 197-200.
| 靶点 | 药物名称 | 临床研究分期 | 状态 | 开始时间 | 试验ID |
|---|---|---|---|---|---|
| 补体C3的RNAi药物 | AROC3-1001 | 1/2a期 | 进行中 | 2022年2月 | NCT05083364 |
| C5aR抑制剂 | avacopan（CCX168） | 2期 | 完成 | 2015年2月 | NCT02384317 |
| C5抑制剂 | 瑞利珠单抗（ravulizumab） | 2期 | 进行中 | 2020年12月 | NCT04564339 |
| ALXN1720 | 1期 | 进行中 | 2022年5月 | NCT05314231 | |
| MASP-2抑制剂 | narsoplimab（OMS721） | 2期 | 完成 | 2016年2月 | NCT02682407 |
| 3期 | 进行中 | 2018年2月 | NCT03608033 | ||
| B因子抑制剂 | iptacopan（LNP023） | 2a/2b期 | 完成 | 2018年2月 | NCT03373461 |
| 3期 | 进行中 | 2021年1月 | NCT04578834 | ||
| 3期 | 进行中 | 2021年9月 | NCT04557462 | ||
| B因子反义抑制剂 | IONIS-FB-LRx | 2a期 | 进行中 | 2019年12月 | NCT04014335 |
| D因子抑制剂 | pelecopan（BCX9930） | 2期 | 进行中 | 2021年10月 | NCT05162066 |
| vemicropan（ALXN2050） | 2期 | 进行中 | 2022年1月 | NCT05097989 |
| [1] |
Robert T, Jantzen R, Cambier A, et al. Spatiotemporal trends and prognosis of end-stage renal disease patients with biopsy-proven immunoglobulin A nephropathy in France from 2010 to 2014[J]. Clin Kidney J, 2021, 14(3):898-908.
doi: 10.1093/ckj/sfaa029 URL |
| [2] |
Schena FP, Nistor I. Epidemiology of IgA nephropathy:a global perspective[J]. Semin Nephrol, 2018, 38(5):435-442.
doi: 10.1016/j.semnephrol.2018.05.013 URL |
| [3] |
Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Long term outcome of immunoglobulin A (IgA) nephropathy: a single center experience[J]. PLoS One, 2021, 16(4): e0249592.
doi: 10.1371/journal.pone.0249592 URL |
| [4] | Medjeral-Thomas NR, Cook HT, Pickering MC. Complement activation in IgA nephropathy[J]. Semin Immuno-pathol, 2021, 43(5): 679-690. |
| [5] |
Poppelaars F, Faria B, Schwaeble W, et al. The contribution of complement to the pathogenesis of IgA nephropathy: are complement-targeted therapies moving from rare disorders to more common diseases?[J]. J Clin Med, 2021, 10(20):4715.
doi: 10.3390/jcm10204715 URL |
| [6] |
Wu L, Liu D, Xia M, et al. Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study[J]. BMC Nephrol, 2021, 22(1): 43.
doi: 10.1186/s12882-021-02237-w pmid: 33514328 |
| [7] |
Tan L, Tang Y, Pei G, et al. A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy[J]. Sci Rep, 2021, 11(1): 5467.
doi: 10.1038/s41598-021-84715-7 pmid: 33750830 |
| [8] |
Wang Z, Jiang Y, Chen P, et al. The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: a cohort study[J]. Nephrol Dial Transplant, 2022, 37(11): 2119-2127.
doi: 10.1093/ndt/gfac024 URL |
| [9] |
Worawichawong S, Plumworasawat S, Liwlompaisan W, et al. Distribution pattern of mesangial C4d deposits as predictor of kidney failure in IgA nephropathy[J]. PLoS One, 2021, 16(6): e0252638.
doi: 10.1371/journal.pone.0252638 URL |
| [10] |
Eder M, Kozakowski N, Omic H, et al. Glomerular C4d in post-transplant IgA nephropathy is associated with decreased allograft survival[J]. J Nephrol, 2021, 34(3): 839-849.
doi: 10.1007/s40620-020-00914-x pmid: 33306182 |
| [11] |
Yeo SC, Liu X, Liew A. Complement factor H gene polymorphism rs6677604 and the risk, severity and progression of IgA nephropathy: a systematic review and meta-analysis[J]. Nephrology (Carlton), 2018, 23(12): 1096-1106.
doi: 10.1111/nep.2018.23.issue-12 URL |
| [12] |
Gyapon-Quast F, Goicoechea de Jorge E, Malik T, et al. Defining the glycosaminoglycan interactions of complement factor H-related protein 5[J]. J Immunol, 2021, 207(2): 534-541.
doi: 10.4049/jimmunol.2000072 pmid: 34193601 |
| [13] |
Medjeral-Thomas NR, Lomax-Browne HJ, Beckwith H, et al. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy[J]. Kidney Int, 2017, 92(4): 942-952.
doi: S0085-2538(17)30256-9 pmid: 28673452 |
| [14] |
Jullien P, Laurent B, Claisse G, et al. Deletion variants of CFHR1 and CFHR3 associate with mesangial immune deposits but not with progression of IgA nephropathy[J]. J Am Soc Nephrol, 2018, 29(2): 661-669.
doi: 10.1681/ASN.2017010019 URL |
| [15] |
Paunas TIF, Finne K, Leh S, et al. Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy[J]. Clin Proteomics, 2017, 14: 30.
doi: 10.1186/s12014-017-9165-x URL |
| [16] |
Zhu L, Guo WY, Shi SF, et al. Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy[J]. Kidney Int, 2018, 94(1): 150-158.
doi: S0085-2538(18)30214-X pmid: 29759419 |
| [17] |
Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy[J]. Semin Immunopathol, 2021, 43(5): 717-728.
doi: 10.1007/s00281-021-00888-3 pmid: 34495361 |
| [18] |
Hu X, Feng J, Deng S, et al. Anaphylatoxins enhance Th9 cell recruitment via the CCL20-CCR6 axis in IgA nephropathy[J]. J Nephrol, 2020, 33(5): 1027-1036.
doi: 10.1007/s40620-020-00708-1 |
| [19] |
Hu X, Feng J, Zhou Q, et al. Respiratory syncytial virus exacerbates kidney damages in IgA nephropathy mice via the C5a-C5aR1 axis orchestrating Th17 cell responses[J]. Front Cell Infect Microbiol, 2019, 9: 151.
doi: 10.3389/fcimb.2019.00151 URL |
| [20] |
Lee A. Avacopan: first approval[J]. Drugs, 2022, 82(1): 79-85.
doi: 10.1007/s40265-021-01643-6 |
| [21] |
Bruchfeld A, Magin H, Nachman P, et al. C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study[J]. Clin Kidney J, 2022, 15(5): 922-928.
doi: 10.1093/ckj/sfab294 pmid: 35498891 |
| [22] |
Nakamura H, Anayama M, Makino M, et al. Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy[J]. Nephron, 2018, 138(4): 324-327.
doi: 10.1159/000485194 URL |
| [23] |
Guzzo G, Sadallah S, Fodstad H, et al. Case report: a rare truncating variant of the CFHR5 gene in IgA nephropathy[J]. Front Genet, 2021, 12: 529236.
doi: 10.3389/fgene.2021.529236 URL |
| [24] |
Herzog AL, Wanner C, Amann K, et al. First treatment of relapsing rapidly progressive IgA nephropathy with eculizumab after living kidney donation[J]. Transplant Proc, 2017, 49(7): 1574-1577.
doi: 10.1016/j.transproceed.2017.02.044 URL |
| [25] |
McKeage K. Ravulizumab: first global approval[J]. Drugs, 2019, 79(3): 347-352.
doi: 10.1007/s40265-019-01068-2 pmid: 30767127 |
| [26] | Barratt J, Carroll K, Lafayette R. Pos-107 long-term phase 2 efficacy of the masp-2 inhibitor narsoplimab for treatment of severe IgA nephropathy[J]. Kidney Int Rep, 2022, 7(2): S45. |
| [27] |
Lafayette RA, Rovin BH, Reich HN, et al. Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy[J]. Kidney Int Rep, 2020, 5(11): 2032-2041.
doi: 10.1016/j.ekir.2020.08.003 pmid: 33163724 |
| [28] | Barratt J, Rovin B, Zhang H, et al. Pos-546 efficacy and safety of iptacopan in iga nephropathy: results of a randomized double-blind placebo-controlled phase 2 study at 6 months[J]. Kidney Int Rep, 2022. 7(2): S236. |
| [29] | Perkovic V, Rovin B, Zhang H, et al. A multi-center, randomized, double-blind, placebo controlled, parallel group, phase Ⅲ study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients[J]. Nephrol Dial Transplant, 2021, 36 Suppl 1:mo148. |
| [1] | WANG Weiming. Interpretation of Chinese expert consensus on understanding and management of renal anemia in diabetic kidney disease [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 137-140. |
| [2] | LUO Yadan, YUAN Liying, LU Yide, WANG Ziqiu, WANG Zhaohui. Investigation of serum uric acid level in adult patients and analysis of related influencing factors [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 141-145. |
| [3] | OUYANG Yan, CHEN Zijin, ZHANG Qianying, et al. Ruijin Hospital recommendations for diagnosis and treatment of novel coronavirus infection in chronic kidney disease population (2023) [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(01): 28-33. |
| [4] | ZHANG Xiaoyan, XU Jing, QU Bin. Effect of serum vitamin D level on renal function in elderly patients with chronic kidney disease [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 307-312. |
| [5] | ZHANG Chunli, XU Jing, PAN Xiaoxia, HU Xiaofan, LI Ya. Analysis of clinical and histological features of IgG4-related kidney disease [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 214-219. |
| [6] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(05): 366-370. |
| [7] | XUAN Yingli, CHEN Feihong, QIN Li, HE Ruibin, PANG Shiqing, YUAN Jiangzi. Correlation analysis of vitamin D and nocturnal blood pressure in the patients with chronic kidney disease [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(04): 246-250. |
| [8] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 49-52. |
| [9] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 4-9. |
| [10] | WANG Xuejie, CHEN Zijin, DU Wen, GU Feifei, YU Haijin, ZHANG Wen, CHEN Xiaonong. Risk factors of acute kidney injury in the patients with bloodstream infection caused by different pathogens [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 22-26. |
| [11] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 15-17. |
| [12] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 10-14. |
| [13] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 1-3. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
